[go: up one dir, main page]

UY26924A1 - Derivados de fenoxibencilamina como ssri - Google Patents

Derivados de fenoxibencilamina como ssri

Info

Publication number
UY26924A1
UY26924A1 UY26924A UY26924A UY26924A1 UY 26924 A1 UY26924 A1 UY 26924A1 UY 26924 A UY26924 A UY 26924A UY 26924 A UY26924 A UY 26924A UY 26924 A1 UY26924 A1 UY 26924A1
Authority
UY
Uruguay
Prior art keywords
disorders
compounds
phenoxibencilamine
ssri
derivatives
Prior art date
Application number
UY26924A
Other languages
English (en)
Inventor
Alan Stobie
Mark David Andrews
David Hepworth
Donald Stuart Middleton
Mavis Diane Adam
Mark Leonard Elliott
Geoffrey Edward Gymer
Harry Ralph Howard Jr
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0021593A external-priority patent/GB0021593D0/en
Priority claimed from GB0107116A external-priority patent/GB0107116D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of UY26924A1 publication Critical patent/UY26924A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)

Abstract

Compuestos de fórmula general (I) Estos compuestos presentan actividad como inhibidores selectivos de la reabsorción de serotonina (SSRI) y tienen utilidad en diversas áreas terapéuticas, son útiles en el tratamiento o prevención de diversos trastornos, incluídos aquellos en los que está implicada la regulación de la función de los transportadores de monoaminas, tales como depresión, trastornos de hiperactividad con déficit de atención, trastornos obsesivo compulsivo, trastorno de estrés post - traumático, trastornos de abuso de sustancias y disfunción sexual, incluida eyaculación precoz, y a las formulaciones farmacéuticas que contienen tales compuestos.
UY26924A 2000-08-31 2001-08-31 Derivados de fenoxibencilamina como ssri UY26924A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0021593A GB0021593D0 (en) 2000-08-31 2000-08-31 Diphenyl ether compounds useful in therapy
GB0107116A GB0107116D0 (en) 2001-03-21 2001-03-21 Novel compounds

Publications (1)

Publication Number Publication Date
UY26924A1 true UY26924A1 (es) 2002-03-22

Family

ID=26244953

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26924A UY26924A1 (es) 2000-08-31 2001-08-31 Derivados de fenoxibencilamina como ssri

Country Status (32)

Country Link
EP (1) EP1313701A1 (es)
JP (1) JP2004507523A (es)
KR (1) KR20030029889A (es)
CN (1) CN1449380A (es)
AP (1) AP2001002265A0 (es)
AR (1) AR031867A1 (es)
AU (1) AU2001278650A1 (es)
BG (1) BG107544A (es)
BR (1) BR0113610A (es)
CA (1) CA2420969A1 (es)
CZ (1) CZ2003467A3 (es)
DO (1) DOP2001000242A (es)
DZ (1) DZ3414A1 (es)
EA (1) EA200300206A1 (es)
EE (1) EE200300084A (es)
HN (1) HN2001000191A (es)
HR (1) HRP20030141A2 (es)
HU (1) HUP0303385A2 (es)
IL (1) IL154343A0 (es)
IS (1) IS6704A (es)
MA (1) MA26945A1 (es)
MX (1) MXPA03001848A (es)
NO (1) NO20030842L (es)
NZ (1) NZ523951A (es)
OA (1) OA12372A (es)
PA (1) PA8526701A1 (es)
PE (1) PE20020346A1 (es)
PL (1) PL360743A1 (es)
SK (1) SK2012003A3 (es)
TN (1) TNSN01131A1 (es)
UY (1) UY26924A1 (es)
WO (1) WO2002018333A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6436938B1 (en) * 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
US20020107244A1 (en) * 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US20020183306A1 (en) * 2001-05-30 2002-12-05 Pfizer Inc. Combination treatment for sleep disorders including sleep apnea
GB0318706D0 (en) * 2003-08-08 2003-09-10 Pfizer Ltd Selective serotonin reuptake inhibitors in the treatment of disease
CA2554696C (en) 2004-02-13 2009-06-30 Warner-Lambert Company Llc Androgen receptor modulators
US7507860B2 (en) 2004-04-13 2009-03-24 Pfizer Inc. Androgen modulators
CA2562672C (en) 2004-04-22 2009-09-29 Warner-Lambert Company Llc 4-cyano-phenoxy derivatives as androgen modulators
JP4874965B2 (ja) 2004-07-08 2012-02-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲン調節剤
JP2008509983A (ja) * 2004-08-18 2008-04-03 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンモジュレーター
JP2008512438A (ja) * 2004-09-10 2008-04-24 ファイザー・プロダクツ・インク 療法用ジフェニルエーテル系リガンド
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
WO2007010350A1 (en) * 2005-07-19 2007-01-25 Pfizer Products Inc. Synthesis of therapeutic diphenyl ethers
WO2007047397A2 (en) 2005-10-13 2007-04-26 Smithkline Beecham Corporation Phenol ethers as modulators of the opioid receptors
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
CN101511790A (zh) * 2006-06-29 2009-08-19 詹森药业有限公司 取代的氨基甲基苯甲酰胺化合物
EP2049466A1 (en) * 2006-06-29 2009-04-22 Janssen Pharmaceutica N.V. Butyl and butynyl benzyl amine compounds
EP2049473A2 (en) * 2006-06-29 2009-04-22 Janssen Pharmaceutica N.V. Substituted benzyl amine compounds
WO2010059393A1 (en) * 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Serotonin receptor modulators
WO2010059390A1 (en) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Modulators of serotonin receptor
KR101043200B1 (ko) * 2010-11-08 2011-06-21 성시민 호흡용 공기탱크의 공기 충전장치
CN103329114B (zh) 2011-01-27 2015-11-25 惠普发展公司，有限责任合伙企业 与便携设备连接的计算设备
TW202100526A (zh) 2019-03-06 2021-01-01 日商第一三共股份有限公司 吡咯并吡唑衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923283B (en) * 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
EP0714391A1 (en) * 1993-08-19 1996-06-05 Warner-Lambert Company Substituted 2(5h)furanone, 2(5h)thiophenone and 2(5h)pyrrolone derivatives, their preparation and their use as endothelin antagonists
CZ293595A3 (cs) * 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
WO1999047497A2 (en) * 1998-03-13 1999-09-23 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
EE200100441A (et) * 1999-02-23 2002-12-16 Pfizer Products Inc. Monoamiinide taasomastamise inhibiitorid kesknärvisüsteemi haiguste raviks
GB0007884D0 (en) * 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy

Also Published As

Publication number Publication date
DOP2001000242A (es) 2002-05-15
EA200300206A1 (ru) 2003-06-26
PE20020346A1 (es) 2002-05-08
IS6704A (is) 2003-01-30
PL360743A1 (en) 2004-09-20
HUP0303385A2 (hu) 2004-03-01
WO2002018333A1 (en) 2002-03-07
HRP20030141A2 (en) 2003-04-30
CN1449380A (zh) 2003-10-15
CZ2003467A3 (cs) 2004-04-14
BR0113610A (pt) 2003-06-24
PA8526701A1 (es) 2003-07-28
HN2001000191A (es) 2002-03-11
EE200300084A (et) 2005-02-15
TNSN01131A1 (fr) 2005-11-10
DZ3414A1 (fr) 2002-03-07
AP2001002265A0 (en) 2001-09-30
MA26945A1 (fr) 2004-12-20
NO20030842D0 (no) 2003-02-24
MXPA03001848A (es) 2003-06-04
CA2420969A1 (en) 2002-03-07
SK2012003A3 (en) 2004-06-08
NZ523951A (en) 2004-09-24
AU2001278650A1 (en) 2002-03-13
JP2004507523A (ja) 2004-03-11
AR031867A1 (es) 2003-10-08
EP1313701A1 (en) 2003-05-28
IL154343A0 (en) 2003-09-17
BG107544A (bg) 2003-10-31
NO20030842L (no) 2003-04-28
OA12372A (en) 2006-04-17
KR20030029889A (ko) 2003-04-16

Similar Documents

Publication Publication Date Title
UY26924A1 (es) Derivados de fenoxibencilamina como ssri
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
BG108207A (en) Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
UY28150A1 (es) Agentes terapeuticos
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
AR031202A1 (es) Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
KR980000447A (ko) 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
UY28376A1 (es) Agentes terapéuticos
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
CR9834A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofrenia
PA8657201A1 (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4, 5-d] pirimidin-2-ona 3, 5-disustituida y 3, 5, 7 - trisustituida y profarmacos de los mismos
UY28752A1 (es) Agentes terapeuticos
SV2002000504A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb
CU23213A3 (es) Difenilureas sustituidas con omega-carboxiarilo como inhibidores de raf quinasa
PA8493701A1 (es) Compuestos para tratar la obesidad
GT200400136A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibirlaproliferacion celular.
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
BG106912A (en) Diphenyl ether compounds useful in therapy
AR002990A1 (es) Una nueva combinacion de un inhibidor de reabsorcion de 5-ht y un antagonista 5-ht(1a), su uso para la preparacion de medicamentos, una formulacion farmaceutica que la comprende, un procedimiento para la preparacion de dicha combinacion y equipo que contiene dicha combinacion.
AR015448A1 (es) COMBINACIoN DE UN INHIBIDOR DE REABSORCIoN DE 5-HT CON UN ANTAGONISTA O AGONISTA PARCIAL DE H5-HT1B, PROCESO PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA QUE LA CONTIENE, SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR TRASTORNOS AFECTIVOS Y KIT QUE CONTIENE DICHA COMBINACIoN
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
BR0308133A (pt) Forma polimórfica cristalina de cloridrato de irinotecan
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141001